Selected angle: counter_signal

One-sentence thesis

Use of metformin was associated with a significantly better overall and progression-free survival of patients with WHO grade III glioma (HR for OS = 0.30; 95% CI = 0.11-0.81). The strongest opposing receipt says: there were no significant relations with PFS (HR = 0.85; 95% CI = 0.59-1.22) in patients with WHO grade IV glioma.

Interpretation note: This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

Why this is surprising

The value is the collision between receipts, not the isolated positive finding; this is the branch worth testing next.

Evidence receipts

• fact_id=80429 (A_core) — Use of metformin was associated with a significantly better overall and progression-free survival of patients with WHO grade III glioma (HR for OS = 0.30; 95% CI = 0.11-0.81) doi=10.1002/ijc.31783
• fact_id=80432 (A_core) — there were no significant relations with PFS (HR = 0.85; 95% CI = 0.59-1.22) in patients with WHO grade IV glioma doi=10.1002/ijc.31783
• fact_id=80431 (A_core) — there were no significant relations with OS (HR = 0.83; 95% CI = 0.57-1.20) in patients with WHO grade IV glioma doi=10.1002/ijc.31783
• fact_id=165590 (A_core) — preadmission metformin use was associated with 39% lower of 30-day mortality (HR = 0.61, 95% CI: 0.46-0.81, p = 0.007) doi=10.3389/fmed.2021.640785
• fact_id=186225 (A_core) — metformin is associated with 34% lower COVID-19 mortality [odds ratio (OR), 0.66; 95% confidence interval (CI), 0.56-0.78] doi=10.3389/fmed.2021.704666
• fact_id=183308 (A_core) — a combined Odds Ratio of 0.468; 95% CI 0.275-0.799 for the association between HCC and the use of metformin. doi=10.1016/j.aohep.2019.10.005
• fact_id=166319 (A_core) — Metformin (0.1%) combined with rapamycin (14 ppm) robustly extended lifespan, suggestive of an added benefit. doi=10.1111/acel.12496

What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

Limitations

• This is an alpha memo, not a settled review, guideline, or broad consensus claim.
• This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
• Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
• Independent receipts fail to reproduce the claimed contrast.
• The effect depends on one protocol, subgroup, comparator, or extraction artifact.

What would weaken this

• Independent receipts fail to reproduce the claimed contrast.
• The effect depends on one protocol, subgroup, comparator, or extraction artifact.

Strongest counter-evidence

• fact_id=80432 (A_core) — there were no significant relations with PFS (HR = 0.85; 95% CI = 0.59-1.22) in patients with WHO grade IV glioma Source: Use of metformin and survival of patients with high‐grade glioma
• fact_id=80431 (A_core) — there were no significant relations with OS (HR = 0.83; 95% CI = 0.57-1.20) in patients with WHO grade IV glioma Source: Use of metformin and survival of patients with high‐grade glioma

Next extraction

• Extract independent A_core/B_context receipts that test the lead contrast directly.
• Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.